James D’Rozario

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · New England Journal of Medicine · 2018 · 909 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Arnon P. Kater, Jenny Wu, Thomas J. Kipps et al. · Journal of Clinical Oncology · 2020 · 220 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · Blood · 2022 · 151 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Mice Deficient in the Putative Phospholipid Flippase ATP11C Exhibit Altered Erythrocyte Shape, Anemia, and Reduced Erythrocyte Life Span*

Mehmet Yabas, Lucy A. Coupland, Deborah Cromer et al. · Journal of Biological Chemistry · 2014 · 69 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +12

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Arnon P. Kater, Thomas J. Kipps, Barbara Eichhorst et al. · Blood · 2020 · 58 citations

Medicine, Hematology, Oncology +16